All-trans retinoic acid (ATRA) is used successfully in the treatment of acute promyelocytic leukemia (APL). ATRA enhances hematopoietic stem cell self-renewal through retinoic acid receptor (RAR)g activation while promoting differentiation of committed myeloid progenitors through RARa activation. Its lack of success in the treatment of non-APL acute myeloid leukemia (AML) may be related to ATRA's non-selectivity for the RARa and RARg isotypes, and specific RARa activation may be more beneficial in promoting myeloid differentiation. To investigate this hypothesis, the effects of ATRA and the specific RARa agonist NRX195183 was assessed in AML1-ETO (AE)-expressing murine bone marrow (BM) progenitors. ATRA potentiated the in vitro clonogenicity of these cells while NRX195183 had the opposite effect. Morphological and flow cytometric analysis confirmed a predominantly immature myeloid population in the ATRA-treated AE cells while the NRX195183-treated cells demonstrated an increase in the mature myeloid population. Similarly, NRX195183 treatment promoted myeloid differentiation in an AE9a in vivo murine model. In the ATRA-treated AE cells, gene expression analyses revealed functional networks involving SERPINE1 and bone morphogenetic protein 2; AKT phosphorylation was upregulated. Collectively, these findings confirm the contrasting roles of specific RARa and RARg activation in the clonogenicity and differentiation of AE cells with potential significant implications in the treatment of non-APL AML using a specific RARa agonist. Leukemia (2013Leukemia ( ) 27, 1369Leukemia ( -1380 doi:10.1038/leu.2012 Keywords: AML1-ETO; retinoids; RARa; RARg; myeloid differentiation INTRODUCTION All-trans retinoic acid (ATRA), a pan-retinoic acid receptor (RAR) agonist, has been used successfully to induce differentiation in acute promyelocytic leukemia (APL), arising from a t(15;17)(q22;q21) translocation resulting in an aberrant PMLRARa fusion oncoprotein.
INTRODUCTION
All-trans retinoic acid (ATRA), a pan-retinoic acid receptor (RAR) agonist, has been used successfully to induce differentiation in acute promyelocytic leukemia (APL), arising from a t(15;17)(q22;q21) translocation resulting in an aberrant PMLRARa fusion oncoprotein. 1 Its action is likely mediated through RARa activation as retroviral transduction of a single copy of RARa restored ATRA sensitivity to the ATRA-resistant HL-60R cells. 2 However, retrovirally transduced RARg was also able to restore ATRA sensitivity to the HL-60R subclones; 3 suggesting that of the three RAR isotypes, RARa and RARg have the most significant roles in hematopoiesis but their exact roles in inducing myeloid differentiation remain unclear. Moreover, ATRA has been shown to have differential effects on enhancing hematopoietic stem cell (HSC) self-renewal mediated through RARg activation while promoting differentiation of myeloid progenitors, likely mediated through RARa activation. [4] [5] [6] To date, ATRA has not shown promise in treating other non-APL acute myeloid leukemia (AML) subtypes, [7] [8] [9] possibly owing to the non-selectivity of ATRA for the different RAR isotypes. Specifically, the ability of ATRA to mediate self-renewal of normal HSC raises the possibility of ATRA potentially enhancing self-renewal of the leukemia-initiating cells mediated through RARg. In addition, in the majority of non-APL AML cells, including t(8;21) AML1-ETO (AE) AML, RARa2 expression is significantly reduced 10 while RARg expression is maintained by a marked reduction in RARg-specific microRNA expression when compared with CD34
þ cord bloodderived stem cells. This suggests that microRNA-mediated downregulation of RARg in HSCs allows the switch from proliferation to RARa-mediated differentiation. 11 Therefore, we hypothesize that the use of isotype-specific RAR agonists and/or antagonists might prove more beneficial in potentiating myeloid differentiation in non-APL AML.
To further evaluate this hypothesis, we utilized bone marrow (BM) cells harvested from a Cre-inducible conditional AE knock-in murine model, which allows AE expression and its effects on leukemogenesis to be studied in adult mice, 12 thereby circumventing problems with embryonic lethality of earlier AE murine models. 13, 14 Consistent with previous studies, conditional expression of AE in BM progenitors induced enhanced clonogenicity but was insufficient to cause AML unless secondary cooperating mutations were induced. 12, 15 These observations are in keeping with the model of multistep pathogenesis of AML whereby Class I mutations enhance proliferation and/or survival to hematopoietic progenitors while Class II mutations inhibit their differentiation (reviewed in Gilliland et al. 16 ). Using pharmacological levels (1 mM) of ATRA, the clonogenicity of these AE-expressing BM progenitors was markedly enhanced while the specific RARa agonist, NRX195183, attenuated the self-renewal capacity of these cells. Surprisingly, treatment with the specific RARg agonist, NRX204723, did not enhance the clonogenicity of the AE-expressing progenitors; however, combination treatment of NRX204723 and the specific RARa agonist, NRX195183, phenocopied the effects of ATRA. Short-term treatment with NRX195183 in vivo potentiated myeloid differentiation in recipient mice of cells overexpressing the truncated AE gene, AE9a. Collectively, these findings reveal the contrasting roles of specific RARa activation in promoting loss of self-renewal ability and enhancing differentiation in the AE cells while activation of both RARa and RARg promotes clonogenicity of these cells.
MATERIALS AND METHODS

Mice and procedures
C57Bl/6 (CD45.2 þ , B6) mice and the congenic B6.SJL-PtprcaPep3/Boy (CD45.1 þ , Ptprca) mice were purchased from the Animal Resource Centre (ARC, Perth, Australia).
C57Bl/6 AML1-ETO-stop/ þ mice 12 were intercrossed with C57Bl/6 Mx1-Cre þ mice to generate mice harboring both genes in combinations of Mx1-Cre þ or À /AML1-ETO-stop/ þ or À . Six-to ten-week-old Mx1-Cre þ or À /AML1-ETO-stop/ þ or À mice were administered 450 mg of pIpC (Sigma, St Louis, MO, USA) in 100 ml of phosphate-buffered saline (PBS) intraperitoneally alternate daily for seven injections. Two to four weeks post completion of pIpC administration, the mice were culled and AE expression in the hematopoietic tissues was assessed using PCR protocols as described. 12 All experiments were conducted with the approval of and in accordance with the guidelines of the Peter MacCallum Cancer Centre (PMCC) Animal Ethics Committee.
Progenitor cell assays for the AML1-ETO-expressing and control BM cells BM cells were harvested from pIpC-treated Mx1-Cre þ /AML1-ETO-stop/ þ and control mice (genotypes included Mx1-Cre À /AML1-ETO-stop/ À (WT), Mx1-Cre À /AML1-ETO-stop/ þ and Mx1-Cre þ /AML1-ETO-stop/ À ). Colonyforming unit assays were performed using 3% methylcellulose-based media as previously described 17 with the addition of rhEPO 3 U/ml (Janssen-Cilag, North Ryde, NSW, Australia), rmSCF 100 ng/ml, rmIL3 10 ng/ml and rmIL6 1000 U/ml (Peprotech, Rocky Hill, NJ, USA). Myeloid colonies were enumerated on day 7 of culture and pooled, washed and 0.1-5 Â 10 4 cells/ml were replated. Retinoids were added directly at final concentrations of 10 À 6 M ATRA (Sigma Chemicals, St Louis, MO, USA) and NRX195183 (NuRx Pharmaceuticals, Irvine, CA, USA); 10 À 6 M, 2 Â 10
and 5 Â 10 À 6 M NRX204723 (NuRx Pharmaceuticals). Dimethyl sulfoxide (DMSO) in a final concentration of 1:10000 was added to the control (vehicle)-treated cultures. This process was repeated every 7 days for 6 weeks or until loss of self-renewal capacity of these cells, whichever occurred earlier. At the second, fourth and sixth weekly passages following addition of the retinoid, cells were harvested for morphological and flow cytometric analyses of myeloid differentiation markers.
AML1-ETO9a (AE9a) retroviral transduction and transplantation into irradiated Ptprca mice
The MigR1 empty vector and MigR1-AE9a (Addgene, Cambridge, MA, USA) plasmid DNA extraction and purification was performed using the JETSTAR Plasmid Maxiprep Kit protocol (GENOMED GmbH, Lohne, Germany). Fetal liver (FL) cells were harvested from WT CD45.2 þ C57Bl/6 E13.5-E16.5 embryos. The retroviral transfection, transduction and transplantation of FL cells were performed as previously described. 18 Commencing 1 week post transplantation, the CD45.1
þ Ptprca MigR1-AE9a-transplanted mice were administered with DMSO (control) or NRX195183 via oral gavage for 6 days a week for 4 weeks (total of 24 doses) at a dose of 45 mg/kg/day. Retinoid administration was performed as previously described. 17 On week 4 of treatment, 2 and 4 weeks post completion of treatment (corresponding to weeks 5,7 and 9 post transplant), morphological and flow cytometric analyses of the peripheral blood (PB) were performed. Mice were culled and analysis of the hematopoietic tissues undertaken when the mice exhibited signs of illness.
Hematopoietic tissue harvest, morphological and histological analyses
PBs, BMs and spleens were harvested and spleen weights were recorded. Cell counts were done on the Advia 120 Haematology System Analyzer (Siemens Australia, Bayswater, Victoria, Australia). Morphological assessment was performed as previously described. 19 Spleens were dissected and fixed in 10% neutral buffered formalin for sectioning, mounted on slides and stained with hematoxylin and eosin.
Flow cytometric analyses PB red cell lysis was performed using BD Pharm Lyse lysing buffer (BD Pharmingen, San Diego, CA, USA). 1 Â 10 6 PB, BM and spleen cells were incubated at 4 1C in 2.4G2 conditioned media for 15-30 min with phycoerythrin (PE)-conjugated anti-Gr-1 (Ly-6G), fluorescein isothiocyanate (FITC)-conjugated or biotin-conjugated anti-CD11b (Mac-1) and allophycocyanin (APC)-conjugated c-Kit (CD117) antibodies. The biotin-conjugated anti-CD11b antibody was used with a secondary peridinin chlorophyll protein (PerCP)-conjugated Streptavidin antibody when analyzing GFP Gene expression analysis for the retinoid-treated AML1-ETOexpressing BM cells After 2 weeks in 3% methylcellulose-based semisolid culture, colonies arising from AE-expressing BM cells from each mouse were pooled separately, washed and cells divided equally into duplicate samples for DMSO (control), ATRA and NRX195183 treatment for 8 and 24 h. Cells were then cultured in liquid suspension containing cytokines and retinoids as described. At the respective time points, cells were processed for RNA extraction and purification using the RNeasy Mini Kit (Qiagen, Doncaster, Victoria, Australia). RNA samples were then processed on the Mouse Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA). Using packages from Bioconductor, 20 the data for each experiment were loaded into the statistical computer program R. 21 The quality of the chips was assessed using the package affyPLM. [22] [23] [24] One of the sample chips had an abnormal intensity of distributions. Two analyses were then performed and correlated; one with data from all the chips included and another with data from the affected chip downweighted to 0.33. The data were normalized and background corrected using the robust multi-array average expression. 25 Differential expression was assessed using the Affy 26 and Limma 27 packages. For each probe set, pairwise comparisons of the average log 2 expression for each treatment was calculated; adjusted P-values o0.05 were considered differentially expressed. 28 The data acquired have been deposited in the National Center for Biotechnology Information (NCBI)'s Gene Expression Omnibus 29 and are accessible through GEO Series accession number GSE39883 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE39883). The interactions between these differentially expressed genes were then examined using Ingenuity Pathways Analysis (IPA, Ingenuity Systems, Redwood City, CA, USA).
The data were also analyzed using Gene Set Enrichment Analysis 30, 31 (http://www.broadinstitute.org/gsea/). Gene sets from the C2 (curated) set were used to assess for phenotypic enrichment. To determine the null distribution, gene permutation was used and gene sets with a false discovery rate of o0.25 and nominal P-values of o0.05 were considered significantly enriched.
Western blot analyses
Immunoblotting was performed as previously described 19 using 10-20 mg total protein extracts lysed in Tris-radio-immuno precipitation assay lysis buffer. The antibodies used were rabbit anti-panAKT, rabbit antiphosphoAKT (Ser473) (Cell Signaling Technology, Danvers, MA, USA) and mouse anti-Actin (MP Biomedicals, Solon, OH, USA).
Statistical analyses
Survival curves were plotted using the Kaplan-Meier method. The log-rank (Mantel-Cox) test was used to analyze differences between survival curves, and P-values o0.05 were considered significant. Statistical differences between groups were assessed using the Student's paired or unpaired two-tailed t-test. The s.e.m. was used to determine the deviation from the mean.
RESULTS
ATRA potentiates the clonogenicity of AML1-ETO-expressing BM cells Using clonogenic assays, ATRA markedly increased the selfrenewal capacity of these pre-leukemic AE-expressing BM cells by more than 10-fold (Figure 1a) while the normal BM cells predictably extinguished their colony-forming potential by 3 weeks in culture (Figure 1b) . Macroscopically, the granulocytemacrophage colonies arising from the ATRA-treated AE cells were significantly larger and more coalesced in comparison with the DMSO-treated AE cells (Figure 1c ). There was a predominance of immature blasts with a concomitant decrease in the more mature intermediate and terminally differentiated myeloid cells in the ATRA-treated BM cells (Figure 1c-e) .
The specific RARa agonist, NRX195183, reduces the clonogenicity of AML1-ETO-expressing BM cells ATRA, a pan-RAR agonist with relatively similar binding affinities for all three RAR isotypes (K d : RARa 15 nM, RARb 13 nM and RARg 18 nM), demonstrates a 40-fold greater transcriptional activation capacity for RARg than RARa. 32 Furthermore, we have shown that RARg is required for HSC self-renewal in response to ATRA, whereas RARa is redundant for these effects. 6 To further delineate the roles of RARa and RARg in the clonogenic potential of the AE BM cells, the specific RARa agonist NRX195183 (K d : RARa 3 nM, RARb 410 5 nM and RARg 410 5 nM
32
) was evaluated at a dose of 10 À 6 M following verification of its biological activity against WT BM murine cells in clonogenic assays. Figure 2c ). There was a significant reduction in the immature blasts and an increase in the mature myeloid population and macrophages in the NRX195183-treated cells (Figure 2c -e). These changes were, however, no longer statistically significant after 6 weeks in culture with the drug, likely owing to the reduction in the sample numbers of NRX195183-treated AE cells as the majority had extinguished their self-renewal capacity by then.
The specific RARg agonist, NRX204723, does not affect the clonogenicity of the AML1-ETO-expressing BM cells As ATRA potentiated the clonogenicity of AE progenitors while the specific RARa agonist NRX195183 resulted in a loss of self-renewal capacity and enhanced differentiation of these cells, we hypothesized that specific RARg activation may promote self-renewal of the AE BM cells. To evaluate this, the specific RARg agonist NRX204723 (K d : RARa 410 5 nM, RARb 410 5 nM and RARg o10 nM) was studied in a similar experimental design. However, no changes in clonogenicity nor myeloid differentiation was observed in the NRX204723-treated compared with DMSO-treated AE cells (Supplementary Figures 1A-D) .
The specific RARg agonist, NRX204723, in combination with the specific RARa agonist, NRX195183, phenocopies the effect of ATRA on the clonogenicity of the AML1-ETO-expressing BM cells As specific RARg activation did not phenocopy the ATRA effects, we sought to determine if activation of both RARa and RARg would induce self-renewal of the AE-expressing BM progenitors. To evaluate this hypothesis, combination treatment with the specific RARg agonist, NRX204723, and the specific RARa agonist, NRX195183, on these AE progenitors were performed.
The combination treatment of NRX195183 with NRX204723 at three different concentrations of 1:1, 1:2 and 1:5 mM, respectively, consistently showed an increase in the self-renewal capacity of these pre-leukemic AE-expressing BM cells by 14-to 22-fold after 6 weeks of treatment (Figure 3a ). There was a predominance of immature blasts with a concomitant decrease in the more mature intermediate myeloid cells ( Differential gene expression in the ATRA-treated versus DMSO (control)-treated AML1-ETO-expressing BM cells To further investigate the molecular mechanisms underlying the opposing effects on clonogenicity by ATRA and NRX195183 on the pre-leukemic AE BM cells, a gene expression analysis was performed. Owing to the loss of clonogenic potential and change in cellular composition of cultures in the NRX195183-treated AE cells in the later passages, the assay was modified with AE cells initially cultured for 2 weeks in methylcellulose-based semisolid media; then, harvested and treated with retinoid or DMSO (control) in cytokine-containing liquid suspension cultures. The AE cells were then subsequently harvested at 8 and 24 h following drug treatment and RNA extracted to assess for changes in gene expression including temporal differences. This methodology allowed the identification of early changes in retinoid-induced molecular genetic events as opposed to differential gene expression arising from secondary downstream events occurring at a later time point when the AE-expressing cells had been in culture for several weeks.
In the NRX195183-treated versus control-treated AE BM cells, no significant differences in gene expression was found. However, in the ATRA-treated AE BM cells, there were 9 probe sets after 8 h of treatment and 16 probe sets after 24 h of treatment, which were found to be significantly upregulated with an adjusted P-value of o0.05 compared with the control-treated cells (Figure 4a and Table 1 ). Seven out of the nine significant probe sets detected after 8 h of ATRA treatment remained significant after 24 h of ATRA treatment. Analysis of the non-downweighted data revealed differential expression of similar genes by ATRA treatment with three and eight probe sets significantly upregulated at the 8 and 24 h time points, respectively (Supplementary Table 3 ).
The interaction between these differentially expressed genes was examined using IPA to generate functional networks. The top-scoring networks after 24 h of ATRA treatment (Figure 4b ) was associated with cell-to-cell signaling and interaction (P ¼ 1.05
The genes with the highest connectivity were SERPINE1, CARD11 and BMP2 (bone morphogenetic protein 2) with three or more interactions with the other molecules in the network. The top three scoring molecular and cellular biological functions were drug metabolism (P ¼ 1.20
À 2 ). The top five canonical pathways were involved in transforming growth factor-beta (TGFb) signaling (P ¼ 1.99E À 3 ), sphingolipid metabolism (P ¼ 3.86E À 3 ), acute phase response signaling (P ¼ 9.32E À 3 ), RAR activation (P ¼ 9.42E À 3 ) and cardiomyocyte differentiation via BMP receptors (P ¼ 1.56E
À 2 ). Of note, when the gene expression analysis was performed excluding the sample chip with the different distribution pattern, SERPINE1 and BMP2 were still significantly upregulated after 24 h of ATRA treatment.
Further confirmatory analysis with Gene Set Enrichment Analysis was utilized to identify gene sets correlating with the ATRA-or NRX195183-treated AE-expressing cells in comparison 4 cells/ml was replated in methylcellulose as described with the addition of DMSO (10 À 6 M) or ATRA (10 À 6 M) with this process repeated every 7 days for 6 weeks. The number of colonies generated/5 Â 10 4 cells at each weekly enumeration is shown (mean±s.e.m., DMSO n ¼ 6 (D49 n ¼ 5), ATRA n ¼ 6 (D49 n ¼ 5), **P ¼ 0.001, *Po0.05, with DMSO (control) treatment. Using a P-value of o0.05 and a false discovery rate of o0.25, no significant gene sets were enriched in the NRX195183-treated AE cells while 56 significantly enriched gene sets were identified in the ATRA-treated AE cells after 24 h of treatment (Supplementary Table 4 ). Of these, 29% were related to cell cycle regulation (red) (68% growth and proliferation, 32% cell differentiation), 25% related to lipid metabolism (blue), 14% related to inflammatory and immunity responses (green), 7% to hypoxia/stress responses (brown) and 5% related to glutathione/reactive oxygen species metabolism (orange). In contrast, NRX195183-treated AE cells for 3 weeks in semisolid media demonstrated significant enrichment in 86 gene sets, which were predominantly (64%) related to cell cycle regulation (red) (60% growth and proliferation, 40% cell differentiation), 23% related to inflammatory and immunity responses (green), 9% related to apoptosis (orange), 9% related to lipid metabolism (blue), 3% related to stem cell regulation (purple) and 2% to hypoxia/stress responses (brown) (Supplementary Table 5 ). These findings are consistent with the increased self-renewal properties of the AE-expressing progenitors and the NRX195183-induced differentiation of these progenitors through RARa activation.
To further validate the ATRA-mediated increase in clonogenicity, western blotting for expression of total AKT and phospho-AKT The specific RARa agonist NRX195183 promotes myeloid differentiation in an in vivo AML1-ETO9a transductiontransplantation murine model of leukemia To further evaluate the ability of the specific RARa agonist NRX195183 in reducing clonogenicity and enhancing myeloid differentiation of AE-expressing progenitors, short-term in vivo transplants of FL cells overexpressing the truncated oncogenic AE gene, AE9a, were performed. Mice transplanted with the control MigR1 vector-expressing FL cells did not develop leukemia as expected, confirming specificity of the AML1-ETO leukemia from MigR1-AE9a-expressing FL cells. In contrast, the MigR1-AE9a-transplanted mice developed leukemia by 5 weeks post transplant.
Consistent with the in vitro data, total PB white cell count was significantly lower in the NRX195183-treated MigR1-AE9a cohort in comparison with the DMSO control-treated cohort at 2 weeks post completion of treatment (Figure 5a ). The NRX195183-treated MigR1-AE9a cohort showed a significant reduction in the PB (Table 2a and Figure 5b) .
At the time of sacrifice due to illness, the MigR1-AE9a mice developed a marked leukoerythroblastic blood picture and BM infiltration by leukemic blasts (Supplementary Figure 2A) . However, the potentiation in granulocytic differentiation in the PB, BM and spleen persisted in the NRX195183-treated group (Table 2b and Figure 5c and d) . In contrast, PB and BM morphological and flow cytometric analyses in the MigR1-control mice were normal (Table 2b and Supplementary Figure 2B) .
Although treatment with the specific RARa agonist NRX195183 for 4 weeks promoted myeloid differentiation in the MigR1-AE9a-transplanted mice, there was no significant effect on median survival (MigR1-AE9a DMSO ¼ 16.5 weeks; MigR1-AE9a NRX195183 ¼ 15.5 weeks) (Supplementary Figure 2C) . At time of sacrifice 10-11 weeks after ceasing NRX195183, there were no significant differences in the PB leukocyte counts, BM cellularity nor spleen weights in the DMSO (control)-treated in comparison with the NRX195183-treated MigR1-AE9a mice ( Supplementary  Figures 2D-F) .
DISCUSSION
The use of ATRA in the treatment of APL has become the paradigm of targeted therapies whereby ATRA is used as a specific ligand for RARa to induce differentiation of the leukemic blasts. 1 However, its use in non-APL AML has not demonstrated any significant clinical benefits, [7] [8] [9] likely owing to the non-selectivity of ATRA on the RARa and RARg isotypes. In this current study, using the specific RARa agonist, NRX195183, on pre-leukemic AEexpressing murine BM progenitors, the in vitro clonogenicity of these cells was reduced while ATRA had an opposing effect with a marked increase in replating efficiency. Concurrently, there was a predominance of an immature myeloid population in the ATRAtreated AE cells while the NRX195183-treated AE cells showed an increase in the mature myeloid population.
As ATRA is a pan-RAR agonist that modulates greater transcriptional activity through RARg than RARa, 32 these observations concurred with our hypothesis that RARg activation promotes self-renewal of these AE progenitors while RARa activation enhances myeloid differentiation and a loss of clonogenic potential (Figure 6 ). Previous studies have confirmed that ATRA potentiates the self-renewal of the primitive hematopoietic Lin
precursors and delays their differentiation 4, 34 and ATRA-treated hematopoietic LKS þ precursors from WT mice upregulated HoxB4 and Notch 1 expression, which are associated with increased HSC selfrenewal. 6, 35, 36 Moreover, ex vivo ATRA-treated RARg þ / þ and RARa À / À LKS þ cells were capable of long-term multilineage reconstitution in recipient mice while ATRA-treated RARg
þ cells were not, indicating that RARg, not RARa, is required for the maintenance of HSCs in ATRA-treated ex vivo cultures. 6 The AE progenitors were therefore subsequently treated with the specific RARg agonist, NRX204723, to determine if RARg activation was required for the ATRA-mediated potentiation in self-renewal. However, specific RARg activation did not phenocopy the ATRA effects. This may have resulted from the strong transcriptional co-repression imparted by RARa in the unliganded state, 37, 38 thereby affecting the efficacy of the specific RARg agonist. Alternatively, the clonogenic cell in AE progenitors could be of a different cell maturation state to the long-term repopulating HSCs that self-renew in response to ATRA via RARg. Further studies on the AE progenitors using combination treatment with the specific RARg agonist, NRX204723, and the specific RARa agonist, NRX195183, phenocopied the ATRAmediated effects. This suggests that the combination treatment could overcome the RARa-mediated repression, thus allowing complete RARg activation, or that the AE leukemia-initiating cell requires both RARa and RARg activation to self-renew ( Figure 6 ).
Gene expression analysis utilizing the Affy/Limma packages 26, 27 and Gene Set Enrichment Analysis 31 was then undertaken to further delineate the molecular mechanisms and pathways underlying the different phenotypic effects seen with the ATRAtreated in comparison with the specific RARa agonist NRX195183-treated AE cells. No significant differences in gene expression in the NRX195183-treated versus control-treated AE cells were observed. This may have resulted from variations in the culture conditions (semisolid methylcellulose-based versus suspension cultures) and temporal differences of the timing of RNA cell harvest (8 and 24 h post treatment) in comparison with the reduction in clonogenicity seen at 3-5 weeks post treatment. However, at 3 weeks post treatment with NRX195183, the lack of differential gene expression remained, which may have resulted from selection bias of samples with persistent but declining clonogenic potential in comparison with those with loss of selfrenewal capacity in which insufficient cells were harvested for RNA extraction and subsequent gene expression analyses. Moreover, gene expression averaged across all cells may not have detected subtle biological effects induced by NRX195183 treatment on Abbreviations: AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; BM, bone marrow; DMSO, dimethyl sulfoxide.
AE-expressing hematopoietic precursors and progenitors with clonogenic potential as these cells would only represent a subset of the harvested cells used for analysis. However, the ATRA-treated AE cells significantly upregulated several genes with SERPINE1 and BMP2 being the most significant in terms of multiple interactions with other molecules known for their roles in tumourigenesis, including AKT, NF-kb complex and TGFb1 in the top-scoring IPA network. Indeed, our findings confirmed an increase in total AKT expression and active phosphorylated AKT in the ATRA-treated AE-expressing progenitors following 1 week of treatment before its effect on potentiating clonogenicity of these cells, consistent with enhanced mTORC1 signaling promoting protein translation leading to cell growth and proliferation. 39, 40 Consistent with our observations, upregulation of both mRNA and protein levels of SERPINE1, also known as plasminogen activator inhibitor-1 (PAI-1), have been shown with ATRA treatment of vascular smooth muscle cells; 41 this was mediated by RARa, through a non-RARE-dependent binding site. 42 The roles that SERPINE1 has in enhancing tumor progression, invasion and metastasis are varied but are thought to be largely mediated by favoring angiogenesis and increasing proteolysis. High levels of PAI-1 in cancer patients have correlated with inferior survival (reviewed in Duffy et al. 43, 44 Binder et al. 45 ). Overexpression of PAI-1 has been shown to increase proliferation of vascular smooth muscle cells via upregulation of the NF-kb and ERK pathways, 46 while in breast cancer cells, PAI-1 leads to sustained mitogenic cellular signaling through the MEK/ERK and JAK/STAT pathways. 47, 48 Together with the PI3K/AKT signal transduction pathway, the activation of these pathways are known to be vital in promoting cell proliferation and survival in leukemogenesis. 49 BMP-2, a multifunctional growth factor belonging to the TGFb superfamily, is known for its crucial roles in heart, neural, bone and cartilage development and mediates osteoblastic differentiation through PI3K-dependent AKT activation (reviewed in Chen et al. 50 ). It has been shown to be a RARg-regulated gene in F9 embryonic teratocarcinoma cells in which ATRA-induced BMP2 upregulation is suppressed with homozygous disruption of RARg. 51 Taken together, the above findings implicate the interactions of multiple pathways known to be involved in cell growth, proliferation and survival in regulating the ATRAmediated increase in clonogenic potential of the pre-leukemic AE progenitors.
Further confirmatory evidence of the ability of the specific RARa agonist, NRX195183, in enhancing myeloid differentiation was observed in an in vivo retroviral AE9a transduction-transplantation murine model of leukemia in which there was a (a) reduction in total PB white cell counts and blast numbers, (b) potentiation in granulocytic differentiation in the GFP þ population after 4 weeks of treatment and (c) persistent increase in both maturing intermediate myeloid cells and mature neutrophils in the GFP þ population in the BM and spleen at the time of sacrifice due to illness in the NRX195183-treated AE9a-transplanted mice. These observations were consistent with previous findings in WT mice of an expansion in PB and splenic granulocytes after 7 days of NRX195183 treatment. 33 Taken together, these findings suggest that the specific RARa agonist, NRX195183, was able to promote myeloid differentiation transiently during and up to 2 weeks post Table 2 . PB and BM morphological analyses of MigR1 and MigR1-AML1-ETO9a-transplanted Ptprca mice as assessed by differential counts 
MigR1-AE9a NRX195183 (n ¼ 10) ATRA promotes clonogenicity of AML1-ETO cells LCY Chee et al completion of treatment but on drug withdrawal, expansion of the blast cell population ultimately eventuated in the mice succumbing to leukemia. Moreover, the inability of NRX195183 treatment to prolong survival in the AE9a-transplanted mice albeit concurrently enhancing myeloid differentiation suggests that 4 weeks of RARa activation alone is insufficient in controlling the leukemic blast cell proliferation and/or survival. These observations are consistent with previous studies showing that leukemogenicity is derived from a combination of Class I and II mutations; therefore, combination therapy of specific RARa agonists with other agents that target cell proliferation and survival, such as conventional chemotherapeutic agents, receptor tyrosine kinase and mammalian target of rapamycin (mTOR)/AKT inhibitors, may be required in treating AE leukemia. In summary, our current study identifies the contrasting roles of specific RARa activation in reducing the clonogenicity and promoting myeloid differentiation in AE-expressing BM progenitors while combined RARa and RARg activation results in the increased self-renewal capacity of these cells. This has potential significant implications in AML treatment as specific RARa agonists may be beneficial in improving the efficacy of other treatment modalities to achieve sustained remission in other non-APL AML subtypes. 
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